Why Menopause Hormone Therapy Remains the Gold Standard

The menopausal transition brings a constellation of changes — vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, bone mineral density loss, shifts in body composition, and for some, cognitive changes. These are driven primarily by declining estradiol, the most biologically active form of estrogen.

Menopause hormone therapy (MHT) — sometimes called hormone replacement therapy (HRT) — remains the most effective treatment for vasomotor and genitourinary symptoms of menopause.[1][2] Contemporary evidence strongly supports the preferential use of transdermal estradiol (patches, gels, or sprays) combined with oral micronized progesterone (for those with an intact uterus) as a well-tolerated, evidence-based approach.[2][3]

Why transdermal? Because transdermal estradiol bypasses first-pass liver metabolism, it avoids the increases in clotting factors, triglycerides, and inflammatory markers (like C-reactive protein) seen with oral estrogen. Observational data suggest lower risks of venous thromboembolism and stroke with transdermal delivery compared to oral formulations.[2][3] Transdermal administration is particularly preferable for women with obesity, hypertriglyceridemia, or migraine with aura.[3]

Why micronized progesterone? For women with an intact uterus, a progestogen is required to protect the endometrium. Observational studies suggest that micronized progesterone carries lower risks of venous thromboembolism and possibly breast cancer compared to synthetic progestins, with fewer negative effects on mood and lipid profiles.[1][3]

MHT and Bone Protection: What Dose and What Level?

Bone loss accelerates dramatically during the menopausal transition. The most rapid bone loss occurs in the transmenopausal phase — the period spanning approximately one year before to two years after the final menstrual period — when lumbar spine bone mineral density (BMD) can decline by over 2% per year.[4] Estradiol is the only hormone consistently shown to have a significant effect on bone mineral density during this transition.[4]

The Women's Health Initiative demonstrated that estrogen therapy (alone or combined with progestin) significantly reduced the risk of clinical fractures (HR 0.71–0.76) and hip fractures (HR 0.65–0.67) compared to placebo.[5]

A key clinical question is: what dose of transdermal estradiol is needed for bone protection? The evidence shows a range of effective doses:

• Even ultra-low-dose transdermal estradiol (0.014 mg/day) is FDA-approved for osteoporosis prevention and has been shown to increase lumbar spine BMD by 2.3% at one year and 3% at two years compared to placebo.[6]
• Doses of 0.025 mg/day and above have consistently demonstrated bone-preserving effects across multiple randomized controlled trials, with higher doses (0.05–0.1 mg/day) producing greater BMD gains at the spine and hip.[7]
• Low-dose oral estradiol (1 mg/day) or transdermal estradiol at 0.0375 mcg/day or less may also be sufficient for many women.[3]

What about serum estradiol levels? Recent research suggests that serum estradiol concentrations of approximately 60 pg/mL — consistent with the mid-follicular phase of a young premenopausal woman — may represent an optimal target for both vasomotor symptom relief and skeletal and cardiovascular benefit.[8] However, there is no one-size-fits-all serum concentration. The optimal level for an individual varies based on tissue sensitivity, the assay method used (immunoassay vs. mass spectrometry), and treatment goals. Dose is typically titrated to symptom response, with serum estradiol measurement used to support clinical decision-making in certain scenarios.[2]

Importantly, older data have shown that postmenopausal women with undetectable serum estradiol (5 pg/mL) have a significantly increased risk of hip and vertebral fracture, and that even maintaining low but detectable estradiol levels may reduce fracture risk by decreasing bone resorption and maintaining osteocyte viability.[9]

MHT and Muscle Mass: What We Know So Far

Estrogen deficiency during menopause is associated with accelerated loss of skeletal muscle mass and function — a process that contributes to sarcopenia.[10] Estradiol appears to play a role in satellite cell proliferation (the cells responsible for muscle repair), membrane stability, and mitochondrial function in skeletal muscle.[11] Longitudinal data from the Women's Health Initiative found that postmenopausal women with higher free estradiol levels had 54% lower odds of sarcopenia compared to those with the lowest levels.[12]

However, the clinical evidence for MHT directly preserving muscle mass is still evolving. A meta-analysis of 12 randomized clinical trials found that hormone therapy users lost only marginally less lean body mass than non-users, and the difference was not statistically significant.[13] That said, a large cross-sectional study of over 4,000 Korean postmenopausal women found that prolonged hormone therapy use was associated with higher appendicular lean mass and a 40% lower prevalence of sarcopenia — particularly in younger (65 years) and leaner women, and with longer duration of use.[14]

The takeaway: MHT likely has a modest protective effect on muscle, but resistance training remains the most evidence-based intervention for preserving muscle mass and function during the menopausal transition. MHT and exercise together may be synergistic.[11][14]

Supplements Are Not a Replacement — But They Can Be Supportive

No supplement replaces the systemic hormonal effects of MHT. Calcium and vitamin D alone, for example, are not adequate for the treatment of osteoporosis.[5] However, targeted supplementation can address specific nutrient gaps and support the constellation of symptoms that accompany the menopausal transition — particularly when used alongside MHT (for those who are candidates) and a foundation of good nutrition and exercise.

The key principle in designing a supplement regimen is bioavailability — ensuring that what you take is actually absorbed and utilized by the body. This is where the science of nutrient interactions becomes critically important, and where a thoughtfully designed supplement protocol differs from simply taking a handful of pills.

The Bivalent Cation Challenge: Why Separation Matters

Iron, calcium, magnesium, and zinc are all divalent (bivalent) cations — positively charged metal ions that share similar absorption pathways in the gut. When taken together, they compete for the same transporters, reducing the absorption of each. This is not theoretical — it has been demonstrated in controlled absorption studies:[15]

• Calcium inhibits both heme and non-heme iron absorption.[15]
• Iron inhibits zinc absorption.
• Zinc can inhibit copper absorption at high doses.

For this reason, a well-designed supplement protocol separates these minerals to minimize competition. Iron, in particular, should be taken apart from calcium, magnesium, and zinc. The remaining bivalent cations (calcium, magnesium, zinc) can be taken together, but the doses should be calibrated so that the total mineral load does not overwhelm absorptive capacity — especially in an immediate-release powder format, where the minerals are rapidly available for absorption.

We explored the biochemistry and pharmacokinetics of this approach in detail in our previous blog post. Here, the emphasis is on how this strategy complements MHT to support the full spectrum of menopausal health.

A Closer Look at Each Supplement and Its Role

Iron (for documented iron deficiency)

Many perimenopausal women experience heavy or irregular menstrual bleeding, which can lead to iron deficiency — even before frank anemia develops. Iron is essential for oxygen transport, energy metabolism, and immune function.

A critical insight from recent research is that iron absorption is regulated by hepcidin, a liver-produced hormone that rises after an iron dose and suppresses further absorption for up to 48 hours. This means that taking iron more than once a day is counterproductive — it increases side effects without improving absorption.[15] Alternate-day dosing has been shown to improve fractional iron absorption by minimizing hepcidin-mediated suppression, with similar efficacy and significantly fewer gastrointestinal side effects (nausea, stomach pain) compared to daily dosing.[15]

A sub-therapeutic daily dose of elemental iron (lower than the traditional 60–65 mg) can leverage this same physiology: by keeping the dose modest, hepcidin elevation is blunted, and day-over-day absorption remains more consistent — functionally mimicking the benefits of alternate-day dosing while maintaining a daily routine.

Iron should be taken on an empty stomach when possible, separated from calcium, magnesium, zinc, tea, and coffee by at least one hour.[15]

Vitamin C (to enhance iron absorption)

Vitamin C (ascorbic acid) is a well-established enhancer of non-heme iron absorption. It works by reducing ferric iron (Fe³⁺) to the more absorbable ferrous form (Fe²⁺) and by forming a soluble chelate that prevents iron from binding to absorption inhibitors like phytates and polyphenols. Taking iron with approximately 80–500 mg of vitamin C on an empty stomach has been shown to improve iron absorption.[15] For this reason, vitamin C is paired with iron in the supplement protocol — taken at the same time, and separated from the other bivalent cations.

Vitamin D3 (bone health and beyond)

Vitamin D is essential for calcium absorption and bone mineralization. The recommended daily allowance for postmenopausal women is 600–800 IU/day, though many clinicians target serum 25-hydroxyvitamin D levels above 20–30 ng/mL.[5] Combined calcium and vitamin D supplementation has been associated with a reduction in hip fracture risk (RR 0.81–0.84) in meta-analyses of randomized trials, particularly in older women and those in institutional settings.[16]

Vitamin D also plays roles in immune modulation and muscle function. A systematic review for the International Menopause Society found high-certainty evidence supporting the safety of vitamin D supplementation and moderate-certainty evidence supporting its role in fracture risk reduction during menopause.

Vitamin D3 is fat-soluble and best absorbed with a meal containing dietary fat. It does not compete with bivalent cation absorption and can be taken with any meal.

Calcium (bone health)

Calcium is the primary structural mineral in bone. The recommended daily allowance is 1,000 mg/day for women aged 19–50 and 1,200 mg/day for women over 50, preferably obtained from dietary sources.[5] Supplementation is recommended when dietary intake is insufficient, particularly for women on osteoporosis pharmacotherapy, as nearly all validation studies of bone-active medications included calcium and vitamin D in both treatment and control groups.[5]

In the supplement protocol, calcium is grouped with magnesium and zinc (away from iron) to avoid iron-calcium competition. The dose is calibrated to complement — not replace — dietary calcium intake, recognizing that excess supplemental calcium has been associated with increased risk of kidney stones and, in some analyses, cardiovascular events.[17]

Magnesium Bisglycinate (sleep onset, muscle recovery, bone health)

Magnesium is involved in over 300 enzymatic reactions, including energy production, muscle contraction, and bone mineralization. Approximately 60% of the body's magnesium resides in bone. Magnesium bisglycinate (magnesium chelated to the amino acid glycine) is selected for its superior absorption profile compared to magnesium oxide or citrate, and for its reduced likelihood of causing gastrointestinal side effects such as loose stools.

For sleep: A meta-analysis of randomized controlled trials found that magnesium supplementation reduced sleep onset latency by approximately 17 minutes compared to placebo.[18] While the overall evidence base is still developing, the VA/DoD Clinical Practice Guideline on insomnia notes that the Sleep Foundation suggests magnesium glycinate specifically due to its improved absorption profile.[19] Glycine itself has calming properties that may contribute to sleep onset.

For muscle: Magnesium supplementation has been shown to reduce delayed-onset muscle soreness and improve perceived recovery after exercise — relevant for perimenopausal women engaging in the resistance training that is so important for preserving muscle mass.[20]

For bone: Magnesium contributes to bone crystal structure and influences the activity of osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells). Adequate magnesium status supports the bone-protective effects of calcium and vitamin D.

Vitamin B12 and B6 (metabolism and energy)

The menopausal transition is associated with rising homocysteine levels — linked to declining estradiol — which may contribute to endothelial dysfunction and cardiovascular risk.[21] Vitamins B12 and B6 are essential cofactors in homocysteine metabolism, and dietary intake of both has been shown to decline in postmenopausal women.[22]

B12 is critical for red blood cell formation, neurological function, and DNA synthesis. Deficiency can cause fatigue, cognitive changes, and peripheral neuropathy — symptoms that can overlap with and compound menopausal complaints. B6 is involved in over 100 enzymatic reactions related to protein, carbohydrate, and lipid metabolism, as well as neurotransmitter synthesis (including serotonin and GABA, which influence mood and sleep).

Both B vitamins are water-soluble and do not compete with bivalent cation absorption. They support the metabolic foundation upon which MHT and other interventions act.

Zinc (immune health, bone and muscle turnover)

Zinc is a cofactor for numerous enzyme systems involved in immune cell function, wound healing, and bone metabolism. Zinc supplementation has been shown to significantly reduce inflammatory markers (CRP, TNF-α, IL-6) and increase CD4 immune cell levels.[23] In bone, zinc stimulates osteoblast proliferation and differentiation while inhibiting osteoclast-mediated bone resorption — it has a dual anabolic and anti-resorptive effect.[24] Meta-analytic data show that zinc supplementation improves bone mineral density at the femoral neck.[25]

Serum zinc levels are significantly lower in patients with osteoporosis compared to controls, and bone zinc content decreases with aging and postmenopausal status.[24][25] Zinc is grouped with calcium and magnesium in the supplement protocol (away from iron) to optimize absorption of both zinc and iron.

Quercetin (mast cell stabilization and anti-inflammatory support)

The decline in estradiol during perimenopause is associated with increased systemic inflammation and, for some women, a heightened inflammatory and histamine-mediated symptom burden. Mast cells — immune cells that release histamine and pro-inflammatory cytokines — can become more reactive in the setting of estrogen withdrawal.

Quercetin, a flavonoid found naturally in onions, apples, and berries, has demonstrated potent mast cell-stabilizing properties. In laboratory studies, quercetin was more effective than cromolyn (the only marketed mast cell "stabilizer" drug) at inhibiting the release of pro-inflammatory cytokines IL-8 and TNF from human mast cells.[26] It also inhibits IL-6 release in a dose-dependent manner and suppresses NF-κB activation — a central inflammatory signaling pathway.[27][28]

In animal models of estrogen deficiency (ovariectomy), quercetin supplementation improved metabolic parameters, reduced oxidative stress and inflammation in adipose tissue, and attenuated cellular senescence markers.[29] While large-scale human clinical trials specific to menopause are still needed, the mechanistic evidence for quercetin as an anti-inflammatory and mast cell-stabilizing agent is robust, and it may offer support for women experiencing inflammation-driven symptoms during the menopausal transition.

Quercetin is a flavonoid (not a bivalent cation) and does not compete with mineral absorption. It can be taken with any meal.

Putting It All Together: Complementary, Not Competing

The evidence is clear: MHT — specifically transdermal estradiol with micronized progesterone — is the most effective intervention for the core symptoms of menopause and offers meaningful protection for bone health.[1][2][3][5] Supplements do not replace this. What they can do is address the nutritional gaps and specific symptom burdens that accompany the menopausal transition, working alongside MHT (for those who are candidates) to support a more comprehensive approach to health during this life stage.

The thoughtful separation of bivalent cations (iron apart from calcium, magnesium, and zinc), the pairing of vitamin C with iron, and the calibration of mineral doses to optimize bioavailability in an immediate-release format — these are not marketing claims. They are applications of well-established principles of mineral absorption pharmacokinetics, designed to ensure that each nutrient reaches its target.

A Final Note

Every woman's experience of menopause is unique. Candidacy for MHT depends on individual risk factors — including age, time since menopause, cardiovascular risk, history of breast cancer, and risk of venous thromboembolism.[1][5] The decision to use MHT, and the selection of formulation, dose, and route, should be made in partnership with a qualified healthcare provider through shared decision-making.[2]

Similarly, supplementation should be guided by documented deficiencies (such as iron deficiency confirmed by ferritin and iron studies) and individual health goals — not by assumption. A primary care provider, nurse practitioner, or pharmacist can help determine which supplements are appropriate, at what doses, and how they interact with any medications being taken.

This is not medical advice. It is an invitation to be informed, to ask better questions, and to approach the menopausal transition with both the best available evidence and the personalized care every woman deserves.